Cellectis (CLLS) Research & Development (2015 - 2026)
Cellectis (CLLS) recorded quarterly Research & Development of -$27.2 million in Q1 2026, down 11.26% quarter-over-quarter from -$24.4 million in Q4 2025, and down 23.96% on a YoY basis from -$35.8 million in Q1 2025.
Cellectis (CLLS) Research & Development (2015 - 2026) Analysis & Trends
Cellectis' Research & Development history runs 12 years deep, the most recent figure standing at -$27.2 million for Q1 2026.
- In Q1 2026, Research & Development fell 23.96% year-over-year to -$27.2 million; the TTM figure through Mar 2026 stood at -$98.8 million (down 208.63% YoY), while the FY2025 annual figure was -$93.5 million, down 203.29% from the prior year.
- Research & Development was -$27.2 million for Q1 2026 at Cellectis, down from -$24.4 million in the prior quarter.
- In the past five years, Research & Development ranged from a high of $160.2 million in Q4 2024 to a low of -$27.2 million in Q1 2026.
- Historically, Research & Development has averaged -$2.4 million across 5 years, with a median of -$23.1 million in 2025.
- The sharpest annual moves came in 2023 and 2025: Research & Development soared 801.42% in 2023, then slumped 115.25% in 2025.
- A 5-year view of Research & Development shows it stood at -$21.4 million in 2022, then jumped by 801.42% to $150.3 million in 2023, then grew by 6.57% to $160.2 million in 2024, then plunged by 115.25% to -$24.4 million in 2025, then declined by 11.26% to -$27.2 million in 2026.
- The last three Research & Development figures came in at -$27.2 million (Q1 2026), -$24.4 million (Q4 2025), and -$24.1 million (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | R&D (Qtr) |
|---|---|---|---|---|---|
| 1 | Alterity Therapeutics | 925,601.88 Bn | 925,601.85 Bn | - | 4.32 Mn |
| 2 | Belite Bio | 58,560.00 Bn | 58,560.00 Bn | - | 15.66 Mn |
| 3 | Quantum Biopharma | 17,284.41 Bn | 17,284.40 Bn | - | 626,092.00 |
| 4 | Legend Biotech | 2,809.00 Bn | 2,808.71 Bn | 242.10 Mn | -101.30 Mn |
| 5 | Evaxion A | 1,334.43 Bn | 1,334.42 Bn | - | -2.30 Mn |
| 6 | Akari Therapeutics | 1,312.27 Bn | 1,312.26 Bn | - | 1.46 Mn |
| 7 | Psyence Biomedical | 212.16 Bn | 212.16 Bn | - | 357,444.00 |
| 8 | Vertex Pharmaceuticals | 114.83 Bn | 107.58 Bn | 2.59 Bn | 961.60 Mn |
| 9 | Abivax | 91.96 Bn | 91.96 Bn | - | -58.00 Mn |
| 10 | Cellectis | 17.40 Bn | 17.21 Bn | - | -27.19 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -27.19 Mn |
| Dec 31, 2025 | -24.44 Mn |
| Sep 30, 2025 | -24.07 Mn |
| Jun 30, 2025 | -23.08 Mn |
| Mar 31, 2025 | -21.93 Mn |
| Dec 31, 2024 | 160.21 Mn |
| Sep 30, 2024 | -23.83 Mn |
| Jun 30, 2024 | -23.52 Mn |
| Mar 31, 2024 | -22.32 Mn |
| Dec 31, 2023 | 150.34 Mn |
| Sep 30, 2023 | -19.08 Mn |
| Jun 30, 2023 | -22.20 Mn |
| Mar 31, 2023 | -21.42 Mn |
| Dec 31, 2022 | -21.43 Mn |
| Sep 30, 2022 | -23.84 Mn |
| Jun 30, 2022 | -25.63 Mn |
| Mar 31, 2022 | -26.60 Mn |
| Dec 31, 2021 | -29.54 Mn |
| Sep 30, 2021 | -34.32 Mn |
| Jun 30, 2021 | -31.15 Mn |